Annotation Detail
Information
- Associated Genes
- ERBB2
- Associated Variants
-
ERBB2 S310F/Y
ERBB2 S310F/Y - Associated Disease
- colon cancer
- Source Database
- CIViC Evidence
- Description
- Colon cancer patient derived xenografts with HER2 mutations are sensitive to HER2 targeted drugs and the greatest tumor reduction was seen with the combination of a tyrosine kinase inhibitor with trastuzumab.
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/1179
- Gene URL
- https://civic.genome.wustl.edu/links/genes/20
- Variant URL
- https://civic.genome.wustl.edu/links/variants/497
- Rating
- 4
- Evidence Type
- Predictive
- Disease
- Colon Cancer
- Evidence Direction
- Supports
- Drug
- Neratinib,Lapatinib,Trastuzumab
- Evidence Level
- D
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 26243863
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Neratinib | Sensitivity | true |
| Trastuzumab | Sensitivity | true |
| Lapatinib | Sensitivity | true |